Navigation Links
Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
Date:3/20/2013

Basel, Switzerland (PRWEB) March 20, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced its partnership with EpiFemCare, the EU-funded research project that will improve the diagnosis and therapy of breast and ovarian cancer. Genedata scientists will manage, process and analyze terabytes of epigenetic and clinical data from next-generation sequencing, microarray and qPCR experiments to help identify, confirm and clinically validate biomarkers. These should lead to significant improvements in early cancer detection and subsequent patient care. The project will also use Genedata Expressionist®, the leading data analysis and management platform for oncology research.

One of the project’s research challenges is the management of complex and large datasets produced by next-generation technologies (e.g. like sequencing, Illumina Infinium arrays and digital qPCR). Genedata scientists will use Genedata Expressionist to identify the most relevant DNA methylation sites, within tens of terabytes of data, which can accurately diagnose breast and ovarian cancer. Resulting biomarkers will be confirmed by independent sample sets and finally validated in large clinical cohorts with over 200,000 patient samples from which over 7,000 will be tested. Genedata Expressionist will be used for its intuitive data visualization, rigorous statistical algorithms, innovative biological interpretation and efficient management and integration of data from various sources and different technology platforms.

“Currently, many women face a diagnosis of advanced ovarian cancer or breast cancer over-diagnosis due to lack of suitable early-detection tests and over-zealous screening procedures,” noted Professor Dr. Martin Widschwendter, the EpiFemCare project coordinator, from the Department of Women’s Cancer at the University College London“We look forward to collaborating with Genedata and using their epigenetics and oncology expertise to develop innovative blood-based tests with increased sensitivity to ovarian cancers and increased specificity for breast cancers.

Innovative and collaborative, the EpiFemCare project is partially funded by the European Union Seventh Framework Programme for Research and Innovation (FP7). In addition to Genedata, project collaborators include: Charles University (Prague, Czech Republic); Ludwig Maximilian University (Munich, Germany); EURAM Ltd (Nottingham, United Kingdom); and GATC Biotech (Konstanz, Germany). EpiFemCare research aims to reduce by 50% the number of women who receive a diagnosis of breast or ovarian cancer when that cancer is already advanced, reduce by 50% the number of women who receive unnecessary long-term chemotherapy, and reduce the number of women dying from these female cancers by 20%.

“The EpiFemCare project is tackling the next frontier in the fight against breast and ovarian cancers -- to facilitate early detection of disease and better prediction of therapeutic outcomes -- and we are eager to contribute our epigenetics know-how to EpiFemCare’s success,” said Dr. Othmar Pfannes, CEO of Genedata. “We hope our experience and expertise in the management and analysis of complex datasets in the context of epigenetics and oncology research will help improve methods for screening, diagnosing and personalizing treatment of breast and ovarian cancers.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10543890.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Screener to Present at 10th Annual Ion Channel Retreat
2. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
3. Genedata Screener for HCS Advances Phenotypic Screening
4. Genedata Screener Adopted for all Plate-based Screening by Major Pharmas
5. Genedata Biologics 3.0 Boosts Efficiency Through Standardization
6. Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry
7. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
8. Powerful AAC Device With Intel® i7 Processor Enables Natural Communication for Stroke, ALS and Autism Patients
9. Magnetic actuation enables nanoscale thermal analysis
10. New portable device enables RNA detection from ultra-small sample in only 20 minutes
11. Krishagni Enables University of New South Wales (Australia) to Adopt caTissue Plus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/6/2019)... ... August 06, 2019 , ... The National Science Foundation (NSF) ... community project that will engage middle and early high school students in environmental ... Citizen Science Network for Community Environmental Assessment.” Collaborative partners presenting the authentic science ...
(Date:7/19/2019)... ... July 18, 2019 , ... Global precision ... enlarge their current piezo motion facilities in Lederhose, Germany, increasing their current footprint ... piezo ceramic assembly production in addition to general office space, a significant increase ...
(Date:7/11/2019)... ... July 11, 2019 , ... At the most recent stem cell ... eight military Veterans under the R3 Heroes Program. The Veterans included individuals and families ... Program allow anyone to nominate a military Veteran, teacher or first responder to receive ...
(Date:6/18/2019)... N.J. (PRWEB) , ... June 17, 2019 , ... ... announced that they have entered into an agreement for production and manufacturing of ... for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for ...
Breaking Biology Technology:
(Date:8/1/2019)... ... August 01, 2019 , ... USDM Life Sciences (USDM) announces that Jay Crowley, ... detailed webinar addressing challenges with the upcoming EU MDR IVDR regulations . ... held a variety of positions over his 26 years at the FDA, including developing ...
(Date:7/23/2019)... , ... July 23, 2019 , ... ... personalized, easy-to-understand, web-based genetic counseling, today announced that the company has expanded its ... MUTYH-associated polyposis (MAP), familial hypercholesterolemia (FH), and Parkinson’s disease. , The expanded content ...
(Date:7/19/2019)... ... 2019 , ... VetStem Biopharma has long been a leader in ... result of a two-year research collaboration with Calidi Biotherapeutics, VetStem has signed a worldwide ... VetStem should be able to fast-track this cancer therapy for use in dogs ...
Breaking Biology News(10 mins):